drugset / Trial / NCT03260504
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Phase 1
Terminated
6 enrolled
University of Washington
Merck Sharp & Dohme LLC · collabPrometheus Laboratories · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of aldesleukin when given together with pembrolizumab in treating patients with kidney cancer that has spread to other parts of the body. Aldesleukin may stimulate white blood cells to kill kidney cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to avoid recognition by immune cells. Giving aldesleukin and pembrolizumab may work better in treating patients with kidney cancer.
Timeline
- Start
- 2018-08-28
- Primary completion
- 2022-07-26
- Completion
- 2022-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |
| Subject | aldesleukin | Protein / enzyme biologic | — | Subcutaneous |